Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1997 1
1998 2
1999 2
2000 4
2001 1
2002 6
2003 4
2004 2
2006 1
2007 2
2008 8
2009 8
2010 5
2011 11
2012 19
2013 15
2014 11
2015 7
2016 10
2017 10
2018 8
2019 4
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Results by year
Filters applied: . Clear all
Page 1
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
Bolin K, et al. J Crohns Colitis 2019. PMID 30893421
OBJECTIVES: To examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clinical remission, with a combination of anti-tumour necrosis factor alpha [anti-TNFα] [infliximab] and immunomodulator therapy compared with two different withdrawal strategies: [1] withdrawal of the anti-TNFα therapy; and [2] withdrawal of the immunomodulator therapy, respectively. ...CONCLUSIONS: Combination therapy using a combination of anti-TNFα [infliximab] and an immunomodulator is cost-effective in the treatment of Crohn's disease compared with treatment cycles in which the immunomodulator is withdrawn. ...
OBJECTIVES: To examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clin …
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P, et al. Pharmacoeconomics 2018. PMID 29667146 Free PMC article.
OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn's disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). ...The replacement of the second-line anti-TNF with ustekinumab/vedolizumab and the course of the disease after discontinuation of biologics are influential drivers of the cost-effectiveness....
OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn's disease (CD) treatment with vedolizumab and ustekinumab a …
The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories.
Rao BB, et al. Inflamm Bowel Dis 2017. PMID 27930405 Free PMC article.
BACKGROUND: Patients with Crohn's disease (CD) encompass a heterogeneous disease spectrum, with variable health care utilization and expenditure patterns. Lémann Index (LI) is a metric that quantifies cumulative bowel damage and has shown utility in delineating distinct disease phenotypes. ...
BACKGROUND: Patients with Crohn's disease (CD) encompass a heterogeneous disease spectrum, with variable health care ut …
The cost-effectiveness of infliximab in Crohn's disease.
Smart C and Selinger CP. Expert Rev Pharmacoecon Outcomes Res 2014 - Review. PMID 25138162
Crohn's disease (CD) is a chronic inflammatory condition that can affect any part of the gastrointestinal tract. It leads to severe symptoms and reduced quality of life. ...
Crohn's disease (CD) is a chronic inflammatory condition that can affect any part of the gastrointestinal tract. It leads to s
Cost-effectiveness of Crohn's disease post-operative care.
Wright EK, et al. World J Gastroenterol 2016 - Clinical Trial. PMID 27076772 Free PMC article.
AIM: To define the cost-effectiveness of strategies, including endoscopy and immunosuppression, to prevent endoscopic recurrence of Crohn's disease following intestinal resection. ...Colonoscopy at 18 mo and faecal calprotectin (FC) measurement were used to assess disease recurrence. Administrative data, chart review and patient questionnaires were collected prospectively over 18 mo. ...
AIM: To define the cost-effectiveness of strategies, including endoscopy and immunosuppression, to prevent endoscopic recurrence of Crohn
Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease.
Everhov ÅH, et al. J Crohns Colitis 2018. PMID 30165593
BACKGROUND AND AIMS: Crohn's disease may affect the ability to work and lead to permanent disability. We aimed to investigate work loss in prevalent patients. METHODS: We identified patients with Crohn's disease and general population comparators matched by sex, birth year, healthcare region and education. ...
BACKGROUND AND AIMS: Crohn's disease may affect the ability to work and lead to permanent disability. We aimed to investigate …
Trends and Attributable Costs of Anorectal Involvement in Pediatric Crohn's Disease.
DeLong CG, et al. J Surg Res 2018. PMID 30463706
BACKGROUND: Pediatric Crohn's disease (CD) with anorectal involvement has not been well characterized. We sought to describe trends in the prevalence of pediatric CD with anorectal involvement and its influence on health-care utilization. MATERIALS AND METHODS: Patients (<21 y of age) with an International Classification of Diseases, Ninth Revision diagnosis of CD (555.X) were identified in the Kid's Inpatient Database (2003, 2006, 2009, 2012) and stratified by anorectal involvement based on the International Classification of Diseases, Ninth Revision diagnosis and procedural codes. ...
BACKGROUND: Pediatric Crohn's disease (CD) with anorectal involvement has not been well characterized. We sought to describe t …
Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C, et al. Aliment Pharmacol Ther 2018. PMID 29851091 Free article.
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. ...
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to …
An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013.
Bounthavong M, et al. Res Social Adm Pharm 2017. PMID 27263802
BACKGROUND: Previous estimates of the economic burden of Crohn's disease (CD) varied widely from $2.0 to $18.2 billion per year (adjusted to 2015 $US). ...A secondary aim described expenditure trends in respondents with and without Crohn's disease pre-post FDA approvals of new biologics and the American College of Gastroenterology Crohn's disease treatment guidelines. ...
BACKGROUND: Previous estimates of the economic burden of Crohn's disease (CD) varied widely from $2.0 to $18.2 billion per yea …
Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Hodgson R, et al. Pharmacoeconomics 2018 - Review. PMID 29192397 Free article.
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to submit evidence on the clinical and cost effectiveness of their drug ustekinumab, an interleukin-12/23 inhibitor, for treating moderate-to-severe active Crohn's disease (CD). ...
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to su …
126 results
Jump to page
Feedback